Owned by the Association for International Promotion & Study in Tumors (APSIT)
Articles
Page 1 of 69
-
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:139
-
CREBZF mRNA nanoparticles suppress breast cancer progression through a positive feedback loop boosted by circPAPD4
Breast cancer (BC) negatively impacts the health of women worldwide. Circular RNAs (circRNAs) are a group of endogenous RNAs considered essential regulatory factor in BC tumorigenesis and progression. However,...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:138 -
Metastatic lymph node targeted CTLA4 blockade: a potent intervention for local and distant metastases with minimal ICI-induced pneumonia
Immune checkpoint blockade (ICB) elicits a strong and durable therapeutic response, but its application is limited by disparate responses and its associated immune-related adverse events (irAEs). Previously, i...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:132 -
Disulfidptosis: a new form of programmed cell death
Disulfidptosis, a new form of cell death triggered by disulfide stress, is characterized by the collapse of cytoskeleton proteins and F-actin due to the intracellular accumulation of disulfides. This discovery...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:137 -
Spatial analysis of stromal signatures identifies invasive front carcinoma-associated fibroblasts as suppressors of anti-tumor immune response in esophageal cancer
Increasing evidence indicates that the tumor microenvironment (TME) is a crucial determinant of cancer progression. However, the clinical and pathobiological significance of stromal signatures in the TME, as a...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:136 -
Correction: Complement inhibitor CSMD1 modulates epidermal growth factor receptor oncogenic signaling and sensitizes breast cancer cells to chemotherapy
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:135 -
Therapeutic targeting of P2X4 receptor and mitochondrial metabolism in clear cell renal carcinoma models
Clear cell renal cell carcinoma (ccRCC) is the most common subtype of renal cancer. Large-scale metabolomic data have associated metabolic alterations with the pathogenesis and progression of renal carcinoma a...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:134 -
Integrated proteogenomic characterization reveals an imbalanced hepatocellular carcinoma microenvironment after incomplete radiofrequency ablation
Efforts to precisely assess tumor-specific T-cell immune responses still face major challenges, and the potential molecular mechanisms mediating hepatocellular carcinoma (HCC) microenvironment imbalance after ...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:133 -
Harnessing cancer stem cell-derived exosomes to improve cancer therapy
Cancer stem cells (CSCs) are the key “seeds” for tumor initiation and development, metastasis, and recurrence. Because of the function of CSCs in tumor development and progression, research in this field has i...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:131 -
New insights into the ambivalent role of YAP/TAZ in human cancers
Hippo signaling was first identified in Drosophila as a key controller of organ size by regulating cell proliferation and anti-apoptosis. Subsequent studies have shown that this pathway is highly conserved in ...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:130 -
Chronic psychological stress promotes breast cancer pre-metastatic niche formation by mobilizing splenic MDSCs via TAM/CXCL1 signaling
Emerging studies have identified chronic psychological stress as an independent risk factor influencing breast cancer growth and metastasis. However, the effects of chronic psychological stress on pre-metasta...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:129 -
Targeting PHB1 to inhibit castration-resistant prostate cancer progression in vitro and in vivo
Castration-resistant prostate cancer (CRPC) is currently the main challenge for prostate cancer (PCa) treatment, and there is an urgent need to find novel therapeutic targets and drugs. Prohibitin (PHB1) is a ...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:128 -
Epigenetically silenced lncRNA SNAI3-AS1 promotes ferroptosis in glioma via perturbing the m6A-dependent recognition of Nrf2 mRNA mediated by SND1
Ferroptosis has been linked to tumor progression and resistance to antineoplastic therapy. Long noncoding RNA (lncRNA) exerts a regulatory role in various biological processes of tumor cells, while the functio...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:127 -
Dual inhibition of CDK12 and CDK13 uncovers actionable vulnerabilities in patient-derived ovarian cancer organoids
High grade serous ovarian cancer (HGSOC) is highly lethal, partly due to chemotherapy resistance and limited availability of targeted approaches. Cyclin dependent kinases 12 and 13 (CDK12/13) are promising the...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:126 -
CircZNF215 promotes tumor growth and metastasis through inactivation of the PTEN/AKT pathway in intrahepatic cholangiocarcinoma
Increasing evidence shows that circular RNAs (circRNAs), a novel class of noncoding RNAs, play a crucial role in the development of cancers, including intrahepatic cholangiocarcinoma (iCCA). Nevertheless, thei...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:125 -
Correction: The Hippo pathway efector TAZ induces intrahepatic cholangiocarcinoma in mice and is ubiquitously activated in the human disease
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:124 -
Retraction Note: Long non-coding RNA TPTEP1 inhibits hepatocellular carcinoma progression by suppressing STAT3 phosphorylation
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:123 -
Pancreatic cancer stemness: dynamic status in malignant progression
Pancreatic cancer (PC) is one of the most aggressive malignancies worldwide. Increasing evidence suggests that the capacity for self-renewal, proliferation, and differentiation of pancreatic cancer stem cells ...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:122 -
CRISPR/Cas9-based genome-wide screening of the deubiquitinase subfamily identifies USP3 as a protein stabilizer of REST blocking neuronal differentiation and promotes neuroblastoma tumorigenesis
The repressor element-1 silencing transcription factor (REST), a master transcriptional repressor, is essential for maintenance, self-renewal, and differentiation in neuroblastoma. An elevated expression of RE...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:121 -
Exploring circular MET RNA as a potential biomarker in tumors exhibiting high MET activity
MET-driven acquired resistance is emerging with unanticipated frequency in patients relapsing upon molecular therapy treatments. However, the determination of MET amplification remains challenging using both stan...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:120 -
Cysteine depletion sensitizes prostate cancer cells to agents that enhance DNA damage and to immune checkpoint inhibition
Prostate Cancer (PCa) represents one of the most commonly diagnosed neoplasms in men and is associated with significant morbidity and mortality. Therapy resistance and significant side effects of current treat...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:119 -
Piperlongumine conquers temozolomide chemoradiotherapy resistance to achieve immune cure in refractory glioblastoma via boosting oxidative stress-inflamation-CD8+-T cell immunity
The failure of novel therapies effective in preclinical animal models largely reflects the fact that current models do not really mimic the pathological/therapeutic features of glioblastoma (GBM), in which the...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:118 -
Regulating lactate-related immunometabolism and EMT reversal for colorectal cancer liver metastases using shikonin targeted delivery
There are few effective medications for treating colorectal cancer and liver metastases (CRLM). The interactions among glycolysis, epithelial-mesenchymal transition (EMT), and immune microenvironment contribut...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:117 -
Convergence of YAP/TAZ, TEAD and TP63 activity is associated with bronchial premalignant severity and progression
Bronchial premalignant lesions (PMLs) are composed primarily of cells resembling basal epithelial cells of the airways, which through poorly understood mechanisms have the potential to progress to lung squamou...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:116 -
Precision medicine applied to metastatic colorectal cancer using tumor-derived organoids and in-vitro sensitivity testing: a phase 2, single-center, open-label, and non-comparative study
Patients with colorectal metastatic disease have a poor prognosis, limited therapeutic options, and frequent development of resistance. Strategies based on tumor-derived organoids are a powerful tool to assess...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:115 -
Tumor microenvironmental modification by the current target therapy for head and neck squamous cell carcinoma
Current clinical and observational evidence supports the EXTREME regimen as one of the standards of care for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) followed by the ...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:114 -
Functional characterization of age-dependent p16 epimutation reveals biological drivers and therapeutic targets for colorectal cancer
Methylation of the p16 promoter resulting in epigenetic gene silencing—known as p16 epimutation—is frequently found in human colorectal cancer and is also common in normal-appearing colonic mucosa of aging indivi...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:113 -
Targeting homologous recombination deficiency in uterine leiomyosarcoma
Uterine leiomyosarcoma (uLMS) is a rare and aggressive gynaecological malignancy, with individuals with advanced uLMS having a five-year survival of < 10%. Mutations in the homologous recombination (HR) DNA re...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:112 -
Irbesartan overcomes gemcitabine resistance in pancreatic cancer by suppressing stemness and iron metabolism via inhibition of the Hippo/YAP1/c-Jun axis
Chemoresistance is the main reason for the poor prognosis of pancreatic ductal adenocarcinoma (PDAC). Thus, there is an urgent need to screen out new targets and compounds to reverse chemotherapeutic resistance.
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:111 -
Loss of Ufl1/Ufbp1 in hepatocytes promotes liver pathological damage and carcinogenesis through activating mTOR signaling
Ufm1-specific ligase 1 (Ufl1) and Ufm1-binding protein 1 (Ufbp1), as putative targets of ubiquitin-fold modifier 1 (Ufm1), have been implicated in several pathogenesis-related signaling pathways. However, litt...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:110 -
miR-92a-1-5p enriched prostate cancer extracellular vesicles regulate osteoclast function via MAPK1 and FoxO1
We have previously reported that extracellular vesicles (EVs) derived from osteoblastic, osteoclastic and mixed prostate cancer cells promote osteoclast differentiation and inhibit osteoblast differentiation v...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:109 -
Activation of ACLY by SEC63 deploys metabolic reprogramming to facilitate hepatocellular carcinoma metastasis upon endoplasmic reticulum stress
Tumor cells display augmented capability to maintain endoplasmic reticulum (ER) homeostasis and hijack ER stress pathway for malignant phenotypes under microenvironmental stimuli. Metabolic reprogramming is a ...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:108 -
TRAF3 suppression encourages B cell recruitment and prolongs survival of microbiome-intact mice with ovarian cancer
Ovarian cancer (OC) is known for exhibiting low response rates to immune checkpoint inhibitors that activate T cells. However, immunotherapies that activate B cells have not yet been extensively explored and m...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:107 -
Bispecific T cell-engager targeting oncofetal chondroitin sulfate induces complete tumor regression and protective immune memory in mice
The malaria protein VAR2CSA binds oncofetal chondroitin sulfate (ofCS), a unique chondroitin sulfate, expressed on almost all mammalian cancer cells. Previously, we produced a bispecific construct targeting of...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:106 -
The β-catenin-LINC00183-miR-371b-5p-Smad2/LEF1 axis promotes adult T-cell lymphoblastic lymphoma progression and chemoresistance
High-intensity chemotherapy regimens are often used in adult T-cell lymphoblastic lymphoma (T-LBL) patients. Nevertheless, the response rate remains unsatisfactory due to emergence of chemoresistance. Growing ...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:105 -
Correction: Silencing LCN2 suppresses oral squamous cell carcinoma progression by reducing EGFR signal activation and recycling
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:104 -
Disulfidptosis: a new target for metabolic cancer therapy
Altered metabolism is a hallmark of cancer and presents a vulnerability that can be exploited in cancer treatment. Regulated cell death (RCD) plays a crucial role in cancer metabolic therapy. A recent study ha...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:103 -
Correction: First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumors
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:102 -
Retraction Note: Circular RNA hsa_circ_0001829 promotes gastric cancer progression through miR155-5p/SMAD2 axis
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:101 -
MYC drives platinum resistant SCLC that is overcome by the dual PI3K-HDAC inhibitor fimepinostat
Small cell lung cancer (SCLC) is an aggressive neuroendocrine cancer with an appalling overall survival of less than 5% (Zimmerman et al. J Thor Oncol 14:768-83, 2019). Patients typically respond to front line...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:100 -
High-throughput and targeted drug screens identify pharmacological candidates against MiT-translocation renal cell carcinoma
MiT-Renal Cell Carcinoma (RCC) is characterized by genomic translocations involving microphthalmia-associated transcription factor (MiT) family members TFE3, TFEB, or MITF. MiT-RCC represents a specific subtype o...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:99 -
Correction: Helicobacter pylori-induced NAT10 stabilizes MDM2 mRNA via RNA acetylation to facilitate gastric cancer progression
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:98 -
Toosendanin targeting eEF2 impedes Topoisomerase I & II protein translation to suppress esophageal squamous cell carcinoma growth
Although molecular targets such as HER2, TP53 and PIK3CA have been widely studied in esophageal cancer, few of them were successfully applied for clinical treatment. Therefore, it is urgent to discover novel a...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:97 -
FGFR4 and EZH2 inhibitors synergistically induce hepatocellular carcinoma apoptosis via repressing YAP signaling
Hepatocellular carcinoma (HCC) is one of the most common and lethal cancers worldwide, but current treatment options remain limited and cause serious life-threatening side effects. Aberrant FGFR4 signaling has...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:96 -
Phytogalactolipids activate humoral immunity against colorectal cancer
Colorectal cancer (CRC) is the third most lethal cancer in the world, and its incidence is steadily rising. In this study, we investigated the induction of humoral immunity by a phytogalactolipid enriched frac...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:95 -
Retraction Note: Nuciferine inhibits the progression of glioblastoma by suppressing the SOX2-AKT/STAT3-Slug signaling pathway
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:94 -
Regulation of ERα-dependent breast cancer metastasis by a miR-29a signaling
Malignant breast cancer (BC) remains incurable mainly due to the cancer cell metastasis, which is mostly related to the status of Estrogen receptor alpha (ERα). However, our understanding of the mechanisms thr...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:93 -
Pharmacological induction of membrane lipid poly-unsaturation sensitizes melanoma to ROS inducers and overcomes acquired resistance to targeted therapy
One of the key limitations of targeted cancer therapies is the rapid onset of therapy resistance. Taking BRAF-mutant melanoma as paradigm, we previously identified the lipogenic regulator SREBP-1 as a central ...
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:92 -
Correction: AHSA1 is a promising therapeutic target for cellular proliferation and proteasome inhibitor resistance in multiple myeloma
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:91 -
Correction: CD90 is regulated by notch1 and hallmarks a more aggressive intrahepatic cholangiocarcinoma phenotype
Citation: Journal of Experimental & Clinical Cancer Research 2023 42:88
-
-
-
Official journal of the Regina Elena National Cancer Institute, Scientific Director Gennaro Ciliberto, Rome, Italy
-
- Editorial Board
- Manuscript editing services
- Instructions for Editors
- Sign up for article alerts and news from this journal
Annual Journal Metrics
-
Citation Impact
12.658 - 2-year Impact Factor (2021)
11.663 - 5-year Impact Factor (2021)
2.045 - Source Normalized Impact per Paper (SNIP)
2.350 - SCImago Journal Rank (SJR)Speed
5 days to first decision for all manuscripts (Median)
9 days to first decision for reviewed manuscripts only (Median)Usage
2,694,347 Downloads (2022)
1498 Altmetric mentions (2021)